GI ASCO 2017

Discussion Board › Forums › Announcements › GI ASCO 2017

Viewing 5 posts - 1 through 5 (of 5 total)
  • Author
    Posts
  • January 28, 2017 at 11:53 pm #94008
    marions
    Moderator

    Julie…correct, most likely they were at this conference. We connected with many physicians, researchers and pharma staff.
    Two years ago I resigned from the NCI Hepatobiliary Task Force after serving for 7 years. I had been given the opportunity to represent our cancer in the development of Phase II/III clinical trials. Melinda holds this position now.

    Anyway, I miss the physicians and love re-connecting with them during GI ASCO, San Francisco.
    It’s the perfect place to do so.

    Compared to the annual ASCO conference, this venue pales in size, hence I may see them in Chicago, but everyone has a tight schedule and we simply don’t have much time to talk.

    Hugs,
    Marion

    January 28, 2017 at 8:44 pm #94007
    iowagirl
    Member

    Thank you ladies for attending the conference and Marion for the summary. I’m wondering if this is the same conference that my Mayo oncologist attended recently (would think so).

    Julie

    January 28, 2017 at 7:20 pm #94006
    gavin
    Moderator

    Thanks for the link marion and my thanks as well to Stacie, Donna, Kathi and Melinda to for attending this years conference on behalf of all of us.

    Big hugs to you all,

    Gavin

    January 28, 2017 at 2:38 pm #94005
    lainy
    Spectator

    Stacie, Donna, Kathi, Melinda and Marion, Just want to say a big thank you for all you ladies do. Interesting post and I know your love SFO. Everyone, I am sure appreciates all you do for CC and where would we be without you. Many thanks.

    January 28, 2017 at 12:29 am #12969
    marions
    Moderator

    Stacie, Donna, Kathi, Melinda and I attended ASCO 2017, San Francisco. As mentioned previously, this is my favorite conference as it is restricted to GI malignancies and our cancer is given attention as well.

    Eileen M. O’Reilly, MD, presented on Pancreatic and Hepatobiliary Cancers: Selecting High-Impact Targets

    In summary: We now know that the profile of of intrahepatic is distinctively different from that of extrahepatic cholangiocarcinoma. Although, cytotoxic agents are the only approved treatments for biliary cancer, we are presented with actual opportunities for treatment with targeted agents identified by genomic profiling.
    Targeted approaches for intrahepatic CCA have shown promising results with IDH, FGF fusions and alterations.
    Both, intrahepatic and extraheptic cholangiocarcinoma show promise with drugs for BRAF and ultimately KRAS alterations.

    Some of these drugs are coming to late stage testing. For example IDH mutations inhibitors are now moving into Phase III trials for previously treated biliary cancer patients and are well tolerated. Additionally, immune targeting has potential in biliary cancer. Also, genomic based strategies for a subset of patients appear to be very promising.

    To learn more, please use this link: http://www.ascopost.com/videos/2017-gastrointestinal-cancers-symposium/eileen-m-o-reilly-md-on-pancreatic-and-hepatobiliary-cancers-selecting-high-impact-targets/?utm_medium=Email&utm_source=ExactTarget&utm_campaign=&utm_term=6283558

  • Author
    Posts
Viewing 5 posts - 1 through 5 (of 5 total)
  • The forum ‘Announcements’ is closed to new topics and replies.